10 Best Small-Cap Growth Stocks to Buy Now

7. Capricor Therapeutics, Inc. (NASDAQ:CAPR)

3-Year Sales Growth: 324.93%

Number of Hedge Fund Holders: 14

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a biotechnology company that focuses on developing new treatments for rare diseases. It uses two main approaches called Cell Therapy and Exosome Technology. In Cell Therapy, its lead product is CAP-1002 which uses cells derived from the heart to treat Duchenne muscular dystrophy, which is a severe muscle disorder. On the other hand, the Exosomes are tiny particles that can carry medicines to specific parts of the body.

On January 3, Jason McCarthy, analyst at Maxim Group maintained a Buy rating on the stock with a price target of $25. The analyst expressed optimism about the progress of Deramiocel, which the company is advancing through late-stage clinical trials for Duchenne muscular dystrophy cardiomyopathy. McCarthy also noted that Capricor Therapeutics, Inc. (NASDAQ:CAPR) has requested a priority review for Deramiocel, which could expedite the approval process. If granted, this could result in a faster approval timeline, potentially securing a PDUFA date in the second half of 2025. It is one of the best small-cap growth stocks to buy now.